Program

OPENING CEREMONY

09.00-09.30

SESSION 1: MOLECULAR EPIDEMIOLOGY OF TUMOR VIRUSES

09.30-11.30

Infections Causing Human Cancers
Harald zur Hausen, Deutsches Krebsforschungszentrum, Heidelberg, Germany

EBV Strains and NPC Pathogenesis
Nancy Raab-Traub, University of North Carolina, Chapel Hill, NC, USA

Prevention of Hepatocellular Carcinoma by Immunization against Hepatitis B Virus Infection
Ding-Shinn Chen, National Taiwan University Hospital, Taipei, Taiwan

HPV and the Treatment of Squamous Cell Carcinoma of the Head and Neck
Everett E. Vokes, University of Chicago Medical Center, Chicago, IL, USA

SESSION 2: MULTIDISCIPLINARY THERAPEUTIC APPROACHES

11.50-12.40

Treatment of Liver Cancer
Sheung-tat Fan, The University of Hong Kong, Hong Kong SAR, China

Chemoradiation in NPC
Joseph Wee, Singapore General Hospital, Singapore

POSTER SESSION A

12.40-14.10

SESSION 3: EPSTEIN BARR VIRUS MOLECULAR PATHOBIOLOGY IN TUMORS

14.10-15.40

EBV Molecular Pathobiology
Elliott Kieff, Harvard University, Boston, MA, USA

EBV and Cancer: When Persistent Inspection Goes Bad
Lawrence S. Young, University of Birmingham, Birmingham, United Kingdom

Functional Role of EBV microRNAs
S. Diane Hayward, Johns Hopkins University, Baltimore, MD, USA

SESSION 4: HEPATOCELLULAR CARCINOGENESIS

16.00-17.00

Factors Associated with the Development of HBV-related HCC
Ming-Whei Yu, National Taiwan University, Taipei, Taiwan

HCC Susceptibility Genes in Patients with Hepatitis C
Naoya Kato, University of Tokyo, Tokyo, Japan

RECEPTION

17.15-18.15

SESSION 5: STEM CELLS AND CANCER

09.00-10.00

Stem Cells and Gastric Cancer
JeanMarie Houghton, University of Massachusetts, Worcester, MA, USA

Stem Cells in HCC
Snorri S. Thorgeirsson, NCI-CCR, Bethesda, MD, USA

SESSION 6: CHEMOPREVENTION

10.20-12.50

Chemoprevention in the 21st Century: Genetics, Risk Model, Targeted Chemoprevention
Waun Ki Hong, UT M. D. Anderson Cancer Center, Houston, TX, USA

Efficacy of HPV Vaccination for Prevention of CA Cervix
T. C. Wu, Johns Hopkins Medical Institutions, Baltimore, MD, USA

Immunotherapy of Established Disease Caused by High Risk HPV
Cornelis J. M. Melief, University Hospital, Leiden, The Netherlands

HPV and Human Cancers: Mechanistic Insights
Peter M. Howley, Harvard Medical School, Boston, MA, USA

Would Treatment of HBV/HCV Reduce the Risk of HCC?
Joseph J. Y. Sung, Chinese University of Hong Kong, Hong Kong SAR, China

POSTER SESSION B

12.50-14.15

SESSION 7: CANCER SCREENING

14.15-15.45

Pathogenesis of Pre-neoplastic Lesions of the Stomach: Targets for Prevention
Naomi Uemura, Kure Kyosai Hospital, Kure, Japan

Plasma Nucleic Acids as a Screening and Detection Tool for Cancer
Y. M. Dennis Lo, Chinese University of Hong Kong, Hong Kong SAR, China

HCC Screening
Tony S. K. Mok, Chinese University of Hong Kong, Hong Kong SAR, China

SESSION 8: GASTRIC AND H. PYLORI PATHOPHYSIOLOGY

16.00-17.00

Host and Other Co-factors in Gastric Carcinogenesis
Wai Keung Leung, Chinese University of Hong Kong, Hong Kong SAR, China

H. pylori and Prevention of Gastric Cancer: Promise and Pitfalls
Julie Parsonnet, Stanford University, Stanford, CA, USA

SESSION 9: EPSTEIN BARR VIRUS NASOPHARYNGEAL CARCINOMA PATHOGENESIS

09.00-10.00

EBV Infection and NPC Development
Yi-Xin Zeng, Sut Yat-Sen University of Medical Sciences, Guangzhou, China 

EBV Modulates STAT Signaling in Nasopharyngeal Carcinoma
Honglin Chen, University of Hong Kong, Hong Kong SAR, China

SESSION 10: GENETICS AND CANCER EPIGENETICS

10.20-12.20

Cellular and Viral Oncogenes in NP Cell Transformation
Musheng Zeng, Sun Yat-Sen University of Medical Sciences, Guangzhou, China

Cytogenetic and Molecular Genetic Alterations in Hepatocellular Carcinoma
Natalie Wong, Chinese University of Hong Kong, Hong Kong SAR, China

Epigenetic Identification of Novel Tumor Suppressor Genes in Tumors
Qian Tao, Chinese University of Hong Kong, Hong Kong SAR, China

Genetic and Epigenetic Alterations in EBV-associated Natural Killer Cell Malignancies
Gopesh Srivastava, Queen Mary Hospital, Hong Kong SAR, China

POSTER SESSION C

12.20-13.50

SESSION 11: IMMUNOBIOLOGY OF ONCOGENIC VIRUSES

13.50-14.50

Immunobiology of Genital HPV Infection: Basic and Translational Aspects
Douglas R. Lowy, NCI-CCR, Bethesda, MD, USA

Improving T Cell Therapy for the Treatment of EBV-associated Malignancies
Cliona M. Rooney, The Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA

SESSION 12: NOVEL THERAPEUTICS

15.10-16.40 

Molecular Biology of Hepatocellular Carcinoma and Targeted Therapies
Melanie B. Thomas, UT M. D. Anderson Cancer Center, Houston, TX, USA

EBV and Lytic Activation as a Strategy for Imaging and Treatment
Richard F. Ambinder, Johns Hopkins University, Baltimore, MD, USA

Novel Systemic Therapies for the Treatment of Nasopharyngeal Carcinoma
Brigette B. Ma, Chinese University of Hong Kong, Hong Kong SAR, China

DEPARTURE